NASDAQ · SCPH
Healthcare · Biotechnology
$5.67
Up+$0.00 (+0.00%)
Updated Aug 16, 2026, 8:04 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SCPH does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SCPH.
SCPH research
Company profile and research snapshot.
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 26, 2025 | Craig-Hallum | Hold | — |
| Aug 25, 2025 | Maxim Group | Hold | — |
| Mar 20, 2025 | Maxim Group | Buy | — |
| Mar 20, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 7, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Oct 7, 2025
MannKind Corporation successfully acquired scPharmaceuticals Inc. for $5.35 per share, expanding its cardiometabolic care portfolio and expected to drive double-digit revenue growth through FUROSCIX®, an innovative therapy for heart failure and kidney disease.
businesswire.com · Sep 16, 2025
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of scPharmaceuticals Inc. (NasdaqGS: SCPH) to MannKind Corporation (NasdaqGM: MNKD). Under the terms of the proposed transaction, shareholders of scPharmaceuticals would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving sp.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SCPH.
No results
No recent SID articles mention SCPH.
